Ultrasensitive plasmon enhanced Raman scattering detection of nucleolin using nanochannels of 3D hybrid plasmonic metamaterial
Ultrasensitive plasmon enhanced Raman scattering detection of nucleolin using nanochannels of 3D hybrid plasmonic metamaterial
复制标题
使用 3D 混合等离子体超材料纳米通道对核素进行超灵敏等离子体增强拉曼散射检测
DOI：
10.1016/j.bios.2021.113040
复制
发表时间：
2021
影响因子：
12.6
通讯作者：
Xia Xing-Hua
中科院分区：
文献类型：
--
作者：
Shi Cai-Feng;Li Zhong-Qiu;Wang Chen;Li Jian;Xia Xing-Hua
癌症生物标志物的检测在癌症诊断中具有重要意义。在这项工作中，我们提出了一种使用 3D 混合等离子体超材料 (PM) 对核仁素 (NCL) 进行等离子体增强拉曼散射 (PERS) 检测的超灵敏原位方法。在该适体传感器中，固定在 PM 上的硫醇化互补 DNA (cDNA) 可以与 Rox 标记的 NCL 结合适体 (AS1411-Rox) 杂交，形成刚性双链 DNA (dsDNA)。当NCL在跨膜偏压下通过PM纳米通道时，它与AS1411-Rox相互作用形成G-四联体（G4-AS1411-Rox），导致AS1411-Rox从纳米通道表面释放，报告分子Rox的PERS信号减弱。 PERS信号的这种变化可以在原位记录下来，而不受外部环境的干扰。借助纳米通道的富集功能，该方法能够在10 min内实现NCL的快速检测，检测限低至71 pM。此外，我们的方法显示出优异的特异性、可逆性、均匀性（相对标准偏差~6.86%）和重现性（~6.65%），为可靠的癌症辅助诊断和药物筛选提供了新平台。
Detection of cancer biomarker is of great significance in cancer diagnostics. In this work, we propose an ultrasensitive andin situmethod for plasmon enhanced Raman scattering (PERS) detection of nucleolin (NCL) using a 3D hybrid plasmonic metamaterial (PM). In this aptasensor, thiolated complementary DNA (cDNA) immobilized on PM can hybridize with Rox-labeled NCL-binding aptamer (AS1411-Rox) to form a rigid double-stranded DNA (dsDNA). When NCL passes through the PM nanochannels under a transmembrane voltage bias, it interacts with AS1411-Rox to form G-quadruplexes (G4-AS1411-Rox), resulting in the release of AS1411-Rox from the nanochannels surface and the decrease in PERS signal of the reporter Rox. This change in PERS signals can be recordedin situwithout the interference of external environment. With the help of the enrichment function of nanochannel, the present method is able to achieve fast NCL detection within 10 min with a detection limit as low as 71 pM. Furthermore, our method shows excellent specificity, reversibility, uniformity (relative standard deviation of ~6.86%) and reproducibility (~6.65%), providing a new platform for reliable cancer auxiliary diagnosis and drug screening.